SHR-4602
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Conditions
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Trial Timeline
Aug 1, 2024 → Dec 1, 2026
NCT ID
NCT06516926About SHR-4602
SHR-4602 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06516926. Target conditions include HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors.
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06516926 | Phase 2 | Recruiting |
Competing Products
6 competing products in HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies | Jiangsu Hengrui Medicine | Phase 1/2 | 39 |
| VIR-5818 + pembrolizumab | Merck | Phase 1/2 | 39 |
| ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine | Jazz Pharmaceuticals | Phase 2 | 32 |
| Zanidatamab + Evorpacept | Jazz Pharmaceuticals | Phase 1/2 | 29 |
| ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib | Jazz Pharmaceuticals | Phase 1 | 26 |
| ZW49 | Zymeworks | Phase 1 | 23 |